Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1981;100(3):311-20.
doi: 10.1007/BF00410691.

Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds

N Brock, J Pohl, J Stekar

Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds

N Brock et al. J Cancer Res Clin Oncol. 1981.

Abstract

Urotoxic side effects, especially hemorrhagic cystitis, have so far been a limiting factor in the therapeutic use of cyclophosphamide (Endoxan), ifosfamide (Holoxan), and trofosfamide (Ixoten). The uroprotective agent mesna (Uromitexan) allows regional detoxification in the kidney and the urinary tract, and thus clinical prevention of the urotoxic side effects of the above cytostatics. The uroprotective mechanism of mesna is based on the formation of nontoxic additive compounds with acrolein and 4-hydroxy-metabolites. In the body, mesna is rapidly transformed into its biologically inert disulfide. After glomerular filtration mesna disulfide is rapidly reduced by reacting with the glutathion system and elimination in the urine as a free thiol compound, further detoxifying the aggressive oxazaphosphorine metabolites.

PubMed Disclaimer

References

    1. Anderson EE, Cobb OE, Glenn JF (1967) Cyclophosphamide hemorrhagic cystitis. J Urol 97:857–858 - PubMed
    1. Arnold H, Bourseaux F, Brock N (1958) Neuartige Krebs-Chemotherapeutika aus der Gruppe der zyklischen N-Lost-Phosphamidester. Naturwiss. 45:64–66
    1. Brock N (1972) Pharmacological studies with ifosfamide — A new oxazaphosphorine compound. In: Hejzlar M, Semonsky M, Masak S (eds) Advances in antimicrobial and antineoplastic chemotherapy. Urban & Schwarzenberg, München Berlin Wien, pp 759–761
    1. Brock N (1973) Pharmakologische Untersuchungen mit Trofosfamid (Ixoten), einem neuen Oxazaphssphorinoxid. Med Monatsschr 27:390–394 - PubMed
    1. Brock N (1979) The special position of ifosfamide in the series of cytostatically active oxazaphosphorines. In: Advances in medical oncology, research and education, Vol 5: Basis for cancer therapy. Pergamon Press, Oxford New York, pp 39–47

LinkOut - more resources